{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-056875","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.091005+00:00","generated_at":"2026-05-19T21:38:23.399918+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ocugen signs binding term sheet to license OCU400 gene therapy in Korea; up to $11M upfront & milestones","bullets":["Upfront license fees and near-term development milestones up to $11M.","Sales milestones of $1M per $15M net sales in Korea (or $150M+ in first 10 years).","Royalty of 25% on net sales; Ocugen to manufacture and supply OCU400.","Estimated 15,000 RP patients in Korea; definitive agreement expected within 60 days.","OCU400 in Phase 3 with target BLA filing mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-056875","json":"https://secwatch.observer/filing/0001104659-25-056875.json","markdown":"https://secwatch.observer/filing/0001104659-25-056875.md","text":"https://secwatch.observer/filing/0001104659-25-056875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925056875/0001104659-25-056875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925056875/tm2517307d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:38:23.399918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}